Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture
RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ( CAIAC ) for the Company s remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. ( HIO ), for gross proceeds of PLN 6,700,000 (CAD $2,308,000).
As announced on November 9, 2020, the Company signed a definitive agreement with CAIAC to purchase Helix s remaining holdings in HIO.
On August 28, 2020, CAIAC, as portfolio manager for Biotech Opportunity Fund ( Opportunity Fund ), announced that it acquired control and direction over, and Opportunity Fund had acquired beneficial ownership of, 26,363,172 common shares of the Company, representing approximately 19.
Tetra Bio-Pharma Confirms it is on Track to Receive Government Funding albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Tetra Provides Update on ARDS-003
Tetra Eyes Global Sepsis Market
OTTAWA, ON / ACCESSWIRE / December 21, 2020 /
Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it expects government funding to help accelerate its sepsis and acute respiratory distress syndrome (ARDS) drug development.
As the first Endocannabinoid System (ECS) biotechnology company tackling sepsis, a life-threatening condition associated with COVID-19 and other inflammatory conditions including pneumonia and tumors, we were advised that we have been positively recommended for government funding of our drug candidate ARDS-003 for development as a therapeutic to treat sepsis and ARDS.
Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results
Helix or the
Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.
OVERVIEW
The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 - $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020 included a gain from loss of control in Helix Immuno-Oncology S.A. ( HIO ) of $2,162,000 (2019 - $nil) on September 3, 2020.
On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ( CAIAC ) to purchase the Company s remaining 29.89% holdings in Helix Immuno-Oncology S.A. ( HIO ), for gross proceeds of PLN 6,700,0
Tetra Bio-Pharma Hits Another Milestone Before Year End - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.